Novartis Alzheimer's Drug Exelon Captures 25% Of New Rxs In U.S.
Novartis is finding room for new Rx growth in the Alzheimer's treatment category, where Exelon has nearly doubled its share of new Rxs in the past two months.
Novartis is finding room for new Rx growth in the Alzheimer's treatment category, where Exelon has nearly doubled its share of new Rxs in the past two months.